Our top pick for
Genasys Inc is a scientific & technical instruments business based in the US. Genasys shares (GNSS) are listed on the NASDAQ and all prices are listed in US Dollars. Genasys employs 99 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.17|
|52-week range||$4.92 - $8.32|
|50-day moving average||$5.21|
|200-day moving average||$5.71|
|Wall St. target price||$9.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.28|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||0.39%|
|1 month (2021-09-21)||1.77%|
|3 months (2021-07-21)||-8.50%|
|6 months (2021-04-21)||-26.87%|
|1 year (2020-10-21)||-19.47%|
|2 years (2019-10-21)||54.33%|
|3 years (2018-10-19)||70.63%|
|5 years (2016-10-21)||213.33%|
Valuing Genasys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genasys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genasys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Genasys shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genasys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.7 million.
The EBITDA is a measure of a Genasys's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$45.9 million|
|Operating margin TTM||7.81%|
|Gross profit TTM||$22.6 million|
|Return on assets TTM||2.94%|
|Return on equity TTM||18%|
|Market capitalisation||$181.1 million|
TTM: trailing 12 months
There are currently 321,362 Genasys shares held short by investors – that's known as Genasys's "short interest". This figure is 39.1% down from 527,844 last month.
There are a few different ways that this level of interest in shorting Genasys shares can be evaluated.
Genasys's "short interest ratio" (SIR) is the quantity of Genasys shares currently shorted divided by the average quantity of Genasys shares traded daily (recently around 43842.019099591). Genasys's SIR currently stands at 7.33. In other words for every 100,000 Genasys shares traded daily on the market, roughly 7330 shares are currently held short.
However Genasys's short interest can also be evaluated against the total number of Genasys shares, or, against the total number of tradable Genasys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genasys's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Genasys shares in existence, roughly 10 shares are currently held short) or 0.0112% of the tradable shares (for every 100,000 tradable Genasys shares, roughly 11 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Genasys.
Find out more about how you can short Genasys stock.
We're not expecting Genasys to pay a dividend over the next 12 months.
Over the last 12 months, Genasys's shares have ranged in value from as little as $4.92 up to $8.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genasys's is 0.5132. This would suggest that Genasys's shares are less volatile than average (for this exchange).
Genasys Inc. , a communication company, designs, develops, and commercializes directed and multidirectional sound technologies, voice broadcast products, and location-based mass messaging solutions for emergency warning and workforce management worldwide. The company operates through two segments, Hardware and Software. It provides long range acoustic devices, such as acoustic hailing devices which are used to project sirens and audible voice messages; and Genasys Emergency Management, a unified software platform for cloud, on-premise or hybrid operations. The company also offers Integrated Mass Notification Solutions, including Genasys voice arrays, which project sirens and audible voice messages 60° - 360° with vocal clarity from close range to approximately 14 square kilometers; and GEM software to deliver SMS, text, email, and social media alerts to people at risk in defined geographic areas. It sells its products directly to governments, militaries, end-users, and commercial companies. The company was formerly known as LRAD Corporation.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.